Paolo Gisondi to Biological Products
This is a "connection" page, showing publications Paolo Gisondi has written about Biological Products.
Connection Strength
0.853
-
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. J Allergy Clin Immunol. 2021 Feb; 147(2):558-560.e1.
Score: 0.299
-
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020 08; 183(2):373-374.
Score: 0.290
-
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opin Biol Ther. 2021 02; 21(2):271-277.
Score: 0.076
-
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. J Am Acad Dermatol. 2020 Jul; 83(1):285-287.
Score: 0.072
-
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. J Eur Acad Dermatol Venereol. 2017 May; 31(5):863-869.
Score: 0.058
-
Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol. 2013 May; 168(5):1124-7.
Score: 0.044
-
Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. Dermatol Ther. 2017 Sep; 30(5).
Score: 0.015